SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-1
Document Type: S-1
Date Filed: 2026-05-15
Accession Number: 0001213900-26-057939
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390026057939/ea0290954-s1_synergy.htm

Chunk 2 of 16
Word Count: 1366
Character Count: 8993

Document Content:

asserting intellectual property infringement claims against us; ● the risks related to our planned expansion into additional international markets; ● the risks related to adverse economic conditions; ● the risks related to catastrophic events; ● our ability to retain key personnel, manage our business effectively, and continue to grow; ● the impact of numerous laws and regulations that apply to the manufacture and sale of nutritional supplements, and compliance with these laws and regulations, as they currently exist or as modified in the future, on us and our suppliers; ● the risks related to product recalls; ● the risks related to product liability claims and litigation to prosecute such claims; and ● the other factors described in “ Risk Factors .” These factors should not be construed as exhaustive and should be read with the other cautionary statements in this prospectus and the documents incorporated by reference into this prospectus.

Although we base these forward-looking
statements on assumptions that we believe are reasonable when made, we caution you that forward-looking statements are not guarantees
of future performance and that our actual results of operations, financial condition and liquidity, and industry developments may differ
materially from statements made in or suggested by the forward-looking statements contained in this prospectus and the documents incorporated
by reference into this prospectus. The matters summarized under “Prospectus Summary,” “Risk Factors,”
“Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Business”
and elsewhere in this prospectus and in the documents incorporated by reference into this prospectus could cause our actual results to
differ significantly from those contained in our forward-looking statements. In addition, even if our results of operations, financial
condition and liquidity, and industry developments are consistent with the forward-looking statements contained in this prospectus and
the documents incorporated by reference into this prospectus, those results or developments may not be indicative of results or developments
in subsequent periods.

In light of these risks and
uncertainties, we caution you not to place undue reliance on these forward-looking statements. Any forward-looking statement that we make
in this prospectus and the documents incorporated by reference into this prospectus speaks only as of the date of such statement, and
we undertake no obligation to update any forward-looking statement or to publicly announce the results of any revision to any of those
statements to reflect future events or developments, except as required by applicable law. Comparisons of results for current and any
prior periods are not intended to express any future trends or indications of future performance, unless specifically expressed as such,
and should only be viewed as historical data.

PROSPECTUS SUMMARY

This summary highlights
information contained in greater detail elsewhere or incorporated by reference in this prospectus and does not contain all of the information
that you should consider before deciding to invest in our common stock. You should read the entire prospectus carefully, including the
“Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations”
and our consolidated financial statements and the related notes incorporated by reference in this prospectus, before making an investment
decision. Some of the statements included in this prospectus and the information incorporated by reference herein constitute forward-looking statements.
See “Cautionary Note Regarding Forward-Looking Statements.” Unless otherwise indicated in this prospectus,
“Synergy CHC,” “we,” “us” and “our” refer to Synergy CHC Corp. and, where appropriate,
its subsidiaries.

Our Company

We are a provider of consumer
health care, beauty, and lifestyle products. Our current brand portfolio consists of two marquee brands, FOCUSfactor, a clinically-tested
brain health supplement (this study was performed independently and is not related to any U.S. Food and Drug Administration (“FDA”)
-approved investigational new drug (IND) application) that has been shown to improve memory, concentration and focus, and Flat Tummy,
a lifestyle and wellness brand that provides a suite of nutritional products to help women achieve their nutrition and weight management
goals. Collectively, these brands are referred to as nutraceuticals. Our products are sold through some of the nation’s leading
club, mass drug, and other retailers such as Costco, Amazon.com, Walmart, Walgreens, BJ’s, and The Vitamin Shoppe. Additionally,
we have expanded into Canada and Mexico.

We built our brand portfolio
through strategic acquisitions. We acquired the FOCUSfactor brand in January 2015 for cash consideration of $6.0 million, including earnout.
In November 2015, we acquired our second marquee brand, Flat Tummy, for AUD 10.0 million (approximately $7.0 million), using a mix of
cash and stock. Our capital structure following the acquisitions of our key brands in 2015 has been highly levered, and our focus has
been on paying our debt and, as a result, we do not have the resources to grow our business. We have grown our FOCUSfactor brand from
3 SKUs at acquisition to over 34 SKUs, and our Flat Tummy Brand from 1 SKU to 13 SKUs. We use the term SKU, or stock-keeping unit, to
refer to a product with a unique UPC (Universal Product Code), which is the barcode used to identify products.

We intend to accelerate the
growth of both our FOCUSfactor supplements and FOCUSfactor energy Ready To Drink (RTD) products. Our asset-light business model, in which
we partner with third-party manufacturers to produce our brand offerings, allows us to scale quickly and profitably while satisfying growing
demand.

For the year ended December 31, 2025, our revenue, net income
and EBITDA were $30.4 million, $(12.3) million and $(6.2) million, respectively, as compared to $34.8 million, $2.1 million
and $6.5 million for the prior year. The EBITDA decrease in 2025 was due to the decrease in net income due to many one-time items,
which reduced net income, including a reserve of bad debt of $6.7 million and write-off of inventory of $0.9 million. At December 31,
2024 we had a working capital deficit of $1.1 million. At December 31, 2025 we had a working capital surplus of $1.8 million.
For reconciliation of EBITDA to net income (loss) see “— Non-GAAP Financial Measures” below.

Our Brands

Our flagship brand, FOCUSfactor,
is a brain health nutritional supplement with over 25 years of history and a clinically-tested formula (this study was performed independently
and is not related to any FDA-approved IND application) comprised of a proprietary blend of key brain supporting ingredients along with
vitamins, minerals, and other nutrients. We believe FOCUSfactor is the only product in its category whose entire formula has been shown
to support memory, concentration and focus. Our FOCUSfactor brand consists of over 34 SKUs and is sold primarily through leading retailers
in the United States, including Costco, Amazon.com, Walmart, Walgreens, BJ’s, and The Vitamin Shoppe, in addition to selling direct
to consumer through the FOCUSfactor website. Across three of our key partners, we have increased the number of SKUs sold through the
retailer from the single SKU available at the beginning of our relationships in 2015 and 2016. In addition, we have increased our presence
in retail locations for these key partners, resulting in a significant increase in points of distribution, defined as the number of SKUs
multiplied by the number of retail locations for each retailer. We have also expanded the brand internationally into Canada (2020) and
Mexico (2025).

FOCUSfactor has expanded into
the beverage market with its focus plus energy RTD. According to Zion Research in January 2024, the global beverage market is large ($176
billion in 2022) and growing (projected 8.6% CAGR covering eight years from 2022 through 2030) with an expanding range of functional benefits
such as energy, hydration, cognition/focus, weight loss, gut health and immunity. Examples such as Celsius and Beyond Raw offer dual-benefit
products that deliver fat burning plus energy while C4 Smart Energy and FocusAid deliver focus plus energy. Additionally, consumers are
looking for not only refreshing drinks but health perks such as zero sugar and low-calorie drinks. This consumer shift in preferences
towards more functional benefits can be seen in the evolution of the energy RTD category where originally competitors like Red Bull and
Monster delivered conventional energy, then the category offered more performance energy products with added vitamins and amino acids
in products such as Reign and C4 Performance to products with more natural energy characteristics and then to the dual-benefit energy
products that we see today.